CoChat

Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology.

Open access
Saletu, B, Grunberger, J, Anderer, P, Linzmayer, L, Semlitsch, HV, Magni, G · 1992 · British Journal of Clinical Pharmacology
Cited by 64

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

1. In a double‐blind, placebo‐controlled study the effects of venlafaxine‐a novel nontricyclic compound inhibiting neuronal uptake of serotonin, noradrenaline and to a lesser extent dopamine‐were investigated utilizing EEG brain mapping, psychometric and psychophysiological measures. 2. Sixteen healthy volunteers (eight males, eight females) aged 21‐36 years received randomized and at weekly intervals single oral doses of placebo, 12.5 mg, 25 mg and 50 mg venlafaxine. EEG recordings, psychometric and psychophysiological tests, and evaluation of pulse, blood pressure and side‐effects were carried out at 0, 2, 4, 6, and 8 h. 3. EEG brain mapping demonstrated that venlafaxine exerted a significant action on human brain function as compared with placebo at all three doses, characterized mostly by attenuation of absolute power, increase of relative delta/theta and beta, and decrease of alpha power, as well as by an acceleration of the total centroid fronto‐temporally and by its slowing centrally and parietally. These findings are similar to antidepressants such as imipramine. Topographically, drug‐induced alterations were most pronounced over both fronto‐temporal and the right temporal to temporo‐ occipital regions. 4. Psychometric and psychophysiological investigations demonstrated significant dose‐dependent psychotropic properties of the drug. Multivariate statistics exhibited an improvement of both the noopsyche (e.g. attention, concentration, attention variability, memory, fine motor activity, reaction time performance) and thymopsyche (e.g. drive, wakefulness)) but also significant psychophysiological activation (e.g. in c.f.f., pupillary and skin conductance measures). 5. Time‐efficiency calculations showed significant central effects from the 2nd hour onwards, with increasing differences between placebo and treatment up to the 8th hour. Nausea was the most frequent complaint and appeared dose dependent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.1992.tb04087.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 64

Metadata

Authors
Saletu, B., Grunberger, J., Anderer, P., Linzmayer, L., Semlitsch, H., & Magni, G.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
1992-06
Volume
33
Issue
6
Pages
589-601
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2031134409
Cited by
64
References
2
FWCI
1.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. https://app.cochat.ai/papers/10.1111/j.1365-2125.1992.tb04087.x
The paper
Saletu, B., Grunberger, J., Anderer, P., Linzmayer, L., Semlitsch, H., & Magni, G. (1992). Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.1992.tb04087.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.